BAM
TCON

Bruderman Asset Management’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Bruderman Asset Management’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10
Closed -$3K – 603
2019
Q1 		$3K Hold
10
– – ﹤0.01% 549
2018
Q4 		$1K Buy
+10
New +$2.71K ﹤0.01% 639

Other funds holding TCON

PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XSC
X-Square Capital Guaynabo, Puerto Rico $297M AUM 32.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bruderman Asset Management's TCON Position: Q2 2019 in Review

Bruderman Asset Management sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2019, closing a stake of 10 shares — an estimated $3K sold.

Bruderman Asset Management first reported a position in TCON in Q4 2018 and held it in 2 quarters. The position peaked at $3K in Q1 2019. 25 funds tracked by Wall St. Rank hold TCON as of Q2 2019.

  • Bruderman Asset Management reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Bruderman Asset Management sold 10 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2019, an estimated $3K.
  • Bruderman Asset Management first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 2 quarters.
  • Bruderman Asset Management's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $3K in Q1 2019.
  • 25 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2019.

Based on Bruderman Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.